Go Pro
→ Trump’s “new Petrodollar” exposed (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CCXI
Churchill Capital Corp XI
$13.40
-3.0%		$15.25
$10.07
▼
$19.69
$956.17M1.221.50 million shs923,439 shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$14.09
-0.1%		$11.76
$9.77
▼
$18.30
$2.46B0.2491,794 shs150,499 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CCXI
Churchill Capital Corp XI
+4.22%-4.09%-10.26%+34.76%+1,381,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
+17.19%+13.70%+21.73%+29.81%-7.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CCXI
Churchill Capital Corp XI
$13.40
-3.0%		$15.25
$10.07
▼
$19.69
$956.17M1.221.50 million shs923,439 shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$14.09
-0.1%		$11.76
$9.77
▼
$18.30
$2.46B0.2491,794 shs150,499 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CCXI
Churchill Capital Corp XI
+4.22%-4.09%-10.26%+34.76%+1,381,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
+17.19%+13.70%+21.73%+29.81%-7.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CCXI
Churchill Capital Corp XI
1.00
SellN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.29
Hold$14.875.51% Upside

Current Analyst Ratings Breakdown

Latest CCXI and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Daiwa Securities Group Inc. logo
Daiwa Securities Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
8/18/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (D)
8/3/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E)
7/31/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D)
7/23/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$16.00 ➝ $14.00
7/17/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
7/7/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$20.00 ➝ $17.00
6/29/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CCXI
Churchill Capital Corp XI
$37.20M25.70N/AN/AN/A∞
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$548.51M4.48$2.69 per share5.24$7.31 per share1.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CCXI
Churchill Capital Corp XI
N/A-$1.89N/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$456.91MN/AN/A50.32N/AN/AN/AN/AN/A

Latest CCXI and HCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026H1 2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$0.1450$0.05-$0.0950$0.05$304.16 million$139.14 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CCXI
Churchill Capital Corp XI
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CCXI
Churchill Capital Corp XI
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.06
5.64
5.50

Institutional Ownership

CompanyInstitutional Ownership
CCXI
Churchill Capital Corp XI
81.09%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%

Insider Ownership

CompanyInsider Ownership
CCXI
Churchill Capital Corp XI
8.30%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
CCXI
Churchill Capital Corp XI
N/A71.36 millionN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,796174.47 million168.19 millionNot Optionable

Recent News About These Companies

HUTCHMED (NASDAQ:HCM) Rating Increased to Buy at Daiwa Securities Group
September 3 at 1:05 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hutchmed-nasdaq-hcm-rating-increased-to-buy-at-daiwa-securities-group-2026-09-03/
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
September 3 at 1:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-hutchmed-lands-gsk-deal-worth-up-to-13b-for-kras-egfr-cancer-therapy-2026-09-03/
HUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?
September 3 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-shares-gap-up-whats-next-2026-09-03/
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
September 3 at 11:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4942785-hutchmed-china-limited-hcm-discusses-strategic-partnership-with-gsk-and-licensing-of-oncology
HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%
September 3 at 9:04 AM  |  rttnews.comhttps://www.rttnews.com/3688056/hutchmed-licenses-hmpl-a830-to-gsk-in-1-295-bln-deal-for-cancer-therapy-stock-up-14.aspx
Hutchmed strikes licensing agreement with GSK
September 3 at 9:04 AM  |  thepharmaletter.comT
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
September 3 at 6:33 AM  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098046?snapi
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
September 3 at 4:00 AM  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098034
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
September 3 at 3:51 AM  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098034?snapi
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
September 3 at 1:48 AM  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/hutchmed-china-signs-licensing-deal-with-gsk-experimental-solid-tumour-drug-2026-09-03/
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 2 at 12:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355629/0/en/hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer-therapy.html
HUTCHMED (NASDAQ:HCM) Sees Large Volume Increase - Here's What Happened
September 2 at 11:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-sees-large-volume-increase-heres-what-happened-2026-09-02/
AstraZeneca, Hutchmed succeed in late-stage lung cancer trial for Orpathys, Tagrisso combo
September 1 at 3:28 PM  |  msn.comhttps://www.msn.com/en-us/news/other/astrazeneca-hutchmed-succeed-in-late-stage-lung-cancer-trial-for-orpathys-tagrisso-combo/ar-AA2bmfAS
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving Average - Here's Why
September 1 at 2:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-shares-pass-above-fifty-day-moving-average-heres-why-2026-09-01/
HUTCHMED Reports Positive Phase 3 SANOVO Data For ORPATHYS Plus TAGRISSO In EGFR-Mutant NSCLC
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3686757/hutchmed-reports-positive-phase-3-sanovo-data-for-orpathys-plus-tagrisso-in-egfr-mutant-nsclc.aspx
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing ...
August 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/hutchmed-announces-sanovo-trial-demonstrated-significant-progression-free-survival-benefit-of-orpathys-plus-tagrisso-in-treatment-na-ve-patients-with-met-overexpressing-egfr-mutated-lung-cancer-1036505134
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
August 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353003/0/en/hutchmed-announces-sanovo-trial-demonstrated-significant-progression-free-survival-benefit-of-orpathys-plus-tagrisso-in-treatment-na%c3%afve-patients-with-met-overexpressing-egfr-mutate.html
Guotai Haitong Keeps Their Buy Rating on HUTCHMED (China) (HCM)
August 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HCM/pressreleases/3651387/guotai-haitong-keeps-their-buy-rating-on-hutchmed-china-hcm/
HUTCHMED (China) (HCM) Gets a Buy from BOCOM International Holdings Company
August 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HCM/pressreleases/3655181/hutchmed-china-hcm-gets-a-buy-from-bocom-international-holdings-company/
Hutchmed's ATLED Wins Conditional Approval From NMPA For Intrahepatic Cholangiocarcinoma
August 28, 2026  |  rttnews.comhttps://www.rttnews.com/3685874/hutchmed-s-atled-wins-conditional-approval-from-nmpa-for-intrahepatic-cholangiocarcinoma.aspx
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352471/0/en/hutchmed-announces-nmpa-approval-for-atled-fanregratinib-for-the-treatment-of-patients-with-fgfr2-fusion-rearrangement-intrahepatic-cholangiocarcinoma.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Churchill Capital Corp XI NASDAQ:CCXI

$13.40 -0.42 (-3.04%)
As of 04:00 PM Eastern

Churchill Capital Corp XI is a blank check company.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$14.09 -0.02 (-0.14%)
As of 04:00 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas